Global X Genomics and Biotechnology

Biotech companies

(GNOG)

£5.45

Previous business day’s close price

‑£10.29 (‑65.36%)

max available period

£5.12

£15.84

04 Nov 21

20 Nov 24

Details

ETF description

The Global X Genomics & Biotechnology ETF seeks to invest in companies that potentially stand to benefit from further advances in the field of genomic science, such as companies involved in gene editing, genomic sequencing, genetic medicine/therapy, computational genomics, and biotechnology.

Issuer details

Global X ETFs is a leading provider of specialized thematic and sector‑specific ETFs, with over $50 billion in assets under management as of June 2024. As a subsidiary of Mirae Asset Global Investments, Global X focuses on thematic investing. Founded in 2008 by Bruno del Ama, Global X ETFs is known for its focus on niche and innovative investment themes, allowing investors to access areas of the market experiencing rapid growth and transformation. Notable ETFs include the Global X Robotics & Artificial Intelligence ETF (BOTZ) and the Global X Lithium & Battery Tech ETF (LIT), reflecting Global X’s commitment to providing exposure to cutting‑edge industries and trends.

Index details

The Solactive Genomics Index tracks the companies that generate revenues from Genomics related business. Genomics business operations include the following: (i) gene editing, (ii) genomic sequencing, (iii) development and testing of genetic medicine/therapies, (iv) computational genomics and genetic diagnostics, and/or (v) biotechnology.

This ETF is in collections:

Thematics

Key information

Key investor information

ETF Breakdown

Veracyte Inc

4.7%

Natera Inc

4.6%

CRISPR Therapeutics AG

4.4%

Arrowhead Pharmaceuticals Inc.

4.3%

Bio‑Techne Corp

4.3%

Illumina Inc

4.2%

Avidity Biosciences Inc

4.1%

Qiagen NV

4.1%

Agilent Technologies Inc.

4.0%

BioNTech SE

3.9%

Beam Therapeutics Inc

3.8%

Biomarin Pharmaceutical Inc.

3.8%

Legend Biotech Corp

3.7%

Alnylam Pharmaceuticals Inc

3.7%

Sarepta Therapeutics Inc

3.5%

Ultragenyx Pharmaceutical Inc.

3.5%

Moderna Inc

3.3%

Intellia Therapeutics Inc

3.2%

10x Genomics Inc

3.0%

Genscript Biotech Corporation

2.8%

Myriad Genetics, Inc.

2.7%

Rocket Pharmaceuticals Inc

2.6%

Caredx Inc

2.2%

Gilead Sciences, Inc.

2.2%

Vertex Pharmaceuticals, Inc.

2.1%

Vir Biotechnology Inc

1.5%

Maravai LifeSciences Holdings Inc

1.3%

Pacific Biosciences of California Inc

1.1%

Sangamo Therapeutics Inc

1.0%

Regenxbio Inc

0.9%

Verve Therapeutics Inc

0.8%

Allogene Therapeutics Inc

0.7%

Fulgent Genetics Inc

0.7%

Sana Biotechnology Inc

0.7%

uniQure N.V.

0.6%

Editas Medicine Inc

0.5%

Poseida Therapeutics Inc

0.5%

2seventy bio Inc

0.4%

Caribou Biosciences Inc

0.4%

Lyell Immunopharma Inc

0.3%

Scilex Holding Corp

< 0.1%

Others

0.3%

£5.45

Previous business day’s close price

Capital at risk

Why InvestEngine

Unbeatable value

From commission‑free investing, to zero‑ISA fees, we’re proud of our low fees.
Here's how we're able to do it

Choice of 700+ ETFs

Low cost, diversified, index‑tracking of stock markets, bonds and commodities.
Browse investments

Actionable insights

Know exactly which companies, sectors and regions are in your portfolio.

Powerful automation

Grow your wealth the easy way with automated investing features

Easy diversification

Fractional investing lets you put as little as £1 in any ETF.

DIY or Managed

Build and manage your own portfolio or leave it to us.

ETFs have spreads and annual charges and come with risks like market volatility, liquidity, and concentration, and may not always accurately track their index. Past performance and forecasts are not reliable indicators of future results. The value of your investments, including any income, can rise or fall. You may get back less than you originally invested.